Trial halted early: testing combo therapy for tough bladder cancers
NCT ID NCT01382706
Summary
This study tested whether combining the chemotherapy drug docetaxel with the targeted drug lapatinib could help control advanced bladder cancer that had worsened after initial platinum-based chemotherapy. It aimed to see if this combination could slow cancer growth and was safe for patients. The trial was stopped early and enrolled only 15 people before termination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.